Adjuvants and inactivated polio vaccine: A systematic review

Hawken, Jennifer; Troy, Stephanie B.

doi:10.1016/j.vaccine.2012.09.059

Cited by 43 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,54,[59][60][61] Vaccine adjuvants such as aluminium salts and oil emulsions were heavily studied for use with the parenteral inactivated polio vaccine (IPV), to attempt to reduce vaccine dose and, hence, improve early schedule completion and decrease vaccine costs. 62 However, few adjuvant candidates have been tested for use with live, oral rotavirus vaccines.…”

Section: Rotavirus Vaccine Adjuvantsmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.

show abstract

Section: Rotavirus Vaccine Adjuvantsmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Besides establishing the potential effect of intradermal injection depth on the immune response, the use of adjuvants can improve IPV immunization efficiency and therefore may result in IPV dose sparing and thus cost reduction (3,15). Although colloidal aluminum hydroxide or aluminum phosphate salts have been used with IPV for intramuscular immunization (16)(17)(18)(19)(20), they are not for intradermal use as they cause severe side effects.…”

Section: Introductionmentioning

confidence: 99%

Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles

et al. 2016

View full text Add to dashboard Cite

Purpose The aim of this study was to investigate the depthdependent intradermal immunogenicity of inactivated polio vaccine (IPV) delivered by depth-controlled microinjections via hollow microneedles (HMN) and to investigate antibody response enhancing effects of IPV immunization adjuvanted with CpG oligodeoxynucleotide 1826 (CpG) or cholera toxin (CT). Methods A novel applicator for HMN was designed to permit depth-and volume-controlled microinjections. The applicator was used to immunize rats intradermally with monovalent IPV serotype 1 (IPV1) at injection depths ranging from 50 to 550 μm, or at 400 μm for CpG and CT adjuvanted immunization, which were compared to intramuscular immunization. Results The applicator allowed accurate microinjections into rat skin at predetermined injection depths (50-900 μm), -volumes (1-100 μL) and -rates (up to 60 μL/min) with minimal volume loss (±1-2%). HMN-mediated intradermal immunization resulted in similar IgG and virus-neutralizing antibody titers as conventional intramuscular immunization. No differences in IgG titers were observed as function of injection depth, however IgG titers were significantly increased in the CpG and CT adjuvanted groups (7-fold).Conclusion Intradermal immunogenicity of IPV1 was not affected by injection depth. CpG and CT were potent adjuvants for both intradermal and intramuscular immunization, allowing effective vaccination upon a minimally-invasive single intradermal microinjection by HMN.

show abstract

“…All these children carried HLA-DQB1 alleles conferring moderately increased risk for type 1 diabetes (HLA-DQB1*0302/x, x≠DQB1*0201, *0301, *0602). A comparison group of 251 children received nonadjuvanted IPV [17] at their well baby clinic at the age of 6 and 12 months according to the standard national immunisation programme in Finland at that time (Fig. 1).…”

Section: Methodsmentioning

confidence: 99%

Live attenuated enterovirus vaccine (OPV) is not associated with islet autoimmunity in children with genetic susceptibility to type 1 diabetes: prospective cohort study

et al. 2017

View full text Add to dashboard Cite

Aims/hypothesis Animal and human studies have implied that enterovirus infections may modulate the risk of islet autoimmunity and type 1 diabetes. We set out to assess whether serial administration of live oral poliovirus vaccine (OPV) in early life can influence the initiation of islet autoimmunity in a cohort of genetically predisposed children. Methods OPV was administered to 64 children and a further 251 children received inactivated poliovirus vaccine (IPV). The emergence of type 1 diabetes-associated autoantibodies in serum (autoantibodies to GAD, insulinoma-associated protein 2, insulin and islet cells) was monitored during prospective follow-up. Stool and serum samples were collected for enterovirus detection by RT-PCR.Results Administration of OPV increased enterovirus detected in stool samples from 11.3% to 38.9% (p < 0.001) during the first year of life. During the follow-up (median 11.0 years), at least one autoantibody was detected in 17.2% of children vaccinated with OPVand 19.1% with IPV (p = 0.723). At least two autoantibodies were observed in 3.1% and 6.8% of children, respectively (p = 0.384). Conclusions/interpretation Replication of attenuated poliovirus strains in gut mucosa is not associated with an increased risk of islet autoimmunity. Trial registration ClinicalTrials.gov: NCT02961595

show abstract

Adjuvants and inactivated polio vaccine: A systematic review

Cited by 43 publications

References 40 publications

Options for improving effectiveness of rotavirus vaccines in developing countries

Options for improving effectiveness of rotavirus vaccines in developing countries

Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles

Live attenuated enterovirus vaccine (OPV) is not associated with islet autoimmunity in children with genetic susceptibility to type 1 diabetes: prospective cohort study

Contact Info

Product

Resources

About